Dr. Ho is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5777 E. Mayo Boulevard
Phoenix, AZ 85050- Is this information wrong?
Clinical Expertise
- Alternative Splicing, RNA Splicing, Cell Line, Histone Code, Kidney Neoplasms, Renal cell carcinoma, Therapeutics, Urologic oncology, Hematologic oncology, General medical oncology, Urethral cancer
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
- Baylor College of MedicineClass of 2006
Certifications & Licensure
- SC State Medical License 2023 - 2025
- AZ State Medical License 2012 - 2025
- TX State Medical License 2009 - 2024
- CA State Medical License 2012 - 2021
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award ASCO
- Paul Calabresi Career Development Award (K12) Mayo Clinic Cancer Center
Clinical Trials
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma Start of enrollment: 2010 Dec 14
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2013 May 16
- Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
- Join now to see all
Publications & Presentations
PubMed
- Development of tandem antigen capture ELISAs measuring QSOX1 isoforms in plasma and serum.Calvin Koelbel, Yvette Ruiz, Zijian Wan, Shaopeng Wang, Thai Ho, Douglas Lake> ;Free Radical Biology & Medicine. 2024 Jan 1
- Cancer Associated Macrophage-like Cells Are Prognostic for Highly Aggressive Prostate Cancer in Both the Non-Metastatic and Metastatic Settings.Daniel J Gironda, Raymond C Bergan, R Katherine Alpaugh, Daniel C Danila, Tuan L Chuang, Brenda Y Hurtado, Thai Ho, Daniel L Adams> ;Cancers. 2023 Jul 22
- SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.Tianchu Wang, Ryan T Wagner, Ryan A Hlady, Xiaoyu Pan, Xia Zhao, Sungho Kim, Liguo Wang, Jeong-Heon Lee, Huijun Luo, Erik P Castle, Douglas F Lake, Thai H Ho, Keith D ...> ;Molecular Oncology. 2024 Jan 1
- Join now to see all
Grant Support
- Synthetic Lethal Targeting of SETD2 in Renal Cell CarcinomaNIH-NCI2023–2028
- Deciphering the Interplay Between H3K36 and DNA Methylation in Renal CancerNIH-NCI2018–2023
- Reprogramming Chromatin Modifiers in Kidney CancerDepartment of Defense2017–2020
- Functional characterization of pazopanib or sunitinib on T cell functionNovartis2017–2018
- Study of a Newly Discovered Immune Cell in the Blood and Evaluation of Its Potential Medical ApplicationsDepartment of Defense2015–2016
- Identifying Epigenetically Regulated Pathways to Target Kidney Cancer MetastasesNIH2013–2016
- Papillary Renal Cell and Urothelial Carcinomas Sample SubmissionNational Institutes of Health2013–2014
- The Role of SETD2, a Histone Methyltransferase, in the Development of Renal Cell CarcinomaConquer Cancer Foundation2011–2012
Professional Memberships
- Member
- Member
- Member
Hospital Affiliations
- Mayo Clinic HospitalPhoenix, Arizona
External Links
- Clinical interestshttp://www.mayoclinic.org/biographies/ho-thai-h-m-d-ph-d/bio-20055574
- Research interestshttp://www.mayo.edu/research/faculty/ho-thai-h-m-d-ph-d/bio-20001528?_ga=1.162847804.1074440646.1437538457
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: